Copper neutrophil lymphocyte ratio

These are some thoughts addressing whether Cu(I)NA2  could be used as a medical food to treat various infections in addition to COVID-19 that is making the news as of this posting.   This “proper copper thought was inspired by the study of Qin(2020) study that showed an increase in the neturophil to lymphocyte ratio in severeContinue reading “Copper neutrophil lymphocyte ratio”

cuprous iodide particles

This post is not about how Mitosynergy and BDLbiochem learned of this project.  This post is about some of the crazy stuff going on in trying to find better ways to treat Covid-19.  Many of the treatments proposed to be encapsulated in this nanoparticles are already losing favor. Laboratory Investigation of Effectiveness of Microencapsulated BiocontrolContinue reading “cuprous iodide particles”

Mycoplasma and viral co-infections

2021 update: This is another password protected post from May of 2020. We were actually forward thinking that maybe Covid-19 could be made worse by mycoplasma coinfections. A PubMed search on Mollicute and Coivd-19 reveals as much. Some day we should look at Cu(I)NA2 as an antibacterial for these cell wall lacking bacteria. Corona Viruses,Continue reading “Mycoplasma and viral co-infections”

Blood Flow in Muscles

KGK Synergize “In addition to the possible analgesic effects facilitated by NMDA receptor inhibition, both copper and nicotinic acid are thought to support mitochondrial function by improving cellular respiration, thus increasing ATP production (1-3). Studies investigating muscle pain in relation to occupational work have demonstrated that sore muscle displays changes in structure indicating mitochondrial disturbancesContinue reading “Blood Flow in Muscles”

Symptom Impact Questionnaire Revised

2021 Update This post was originally published in May of 2020 with password protection. We have since published these results on clinicaltrials.gov. While these data have not been peer reviewed for mechanisms of action and so forth, they have undergone rigorous examination by clinicaltrials.gov for consistency and the general safety measures. We’d like to thankContinue reading “Symptom Impact Questionnaire Revised”